Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 245


Using circulating tumor cells to guide therapy in breast cancer: could this replace biopsies?

Dawood S, Cristofanilli M.

Pharmacogenomics. 2015 May 7:1-4. [Epub ahead of print] No abstract available.


Molecular characterization and targeted therapeutic approaches in breast cancer.

Toss A, Cristofanilli M.

Breast Cancer Res. 2015 Apr 23;17(1):60. doi: 10.1186/s13058-015-0560-9.


Blocking the Adhesion Cascade at the Premetastatic Niche for Prevention of Breast Cancer Metastasis.

Kang SA, Hasan N, Mann AP, Zheng W, Zhao L, Morris L, Zhu W, Zhao YD, Suh KS, Dooley WC, Volk D, Gorenstein DG, Cristofanilli M, Rui H, Tanaka T.

Mol Ther. 2015 Mar 27. doi: 10.1038/mt.2015.45. [Epub ahead of print]


Relationship between circulating tumor cells, blood coagulation, and urokinase-plasminogen-activator system in early breast cancer patients.

Mego M, Karaba M, Minarik G, Benca J, Sedlácková T, Tothova L, Vlkova B, Cierna Z, Janega P, Luha J, Gronesova P, Pindak D, Fridrichova I, Celec P, Reuben JM, Cristofanilli M, Mardiak J.

Breast J. 2015 Mar-Apr;21(2):155-60. doi: 10.1111/tbj.12388. Epub 2015 Jan 27.


Circulating tumor cells in newly diagnosed inflammatory breast cancer.

Mego M, Giordano A, De Giorgi U, Masuda H, Hsu L, Giuliano M, Fouad TM, Dawood S, Ueno NT, Valero V, Andreopoulou E, Alvarez RH, Woodward WA, Hortobagyi GN, Cristofanilli M, Reuben JM.

Breast Cancer Res. 2015 Jan 9;17(1):2. doi: 10.1186/s13058-014-0507-6.


Cytometric characterization of circulating tumor cells captured by microfiltration and their correlation to the cellsearch(®) CTC test.

Adams DL, Stefansson S, Haudenschild C, Martin SS, Charpentier M, Chumsri S, Cristofanilli M, Tang CM, Alpaugh RK.

Cytometry A. 2015 Feb;87(2):137-44. doi: 10.1002/cyto.a.22613. Epub 2014 Dec 16.


Cancer stem cells: implications for cancer therapy.

Dawood S, Austin L, Cristofanilli M.

Oncology (Williston Park). 2014 Dec;28(12):1101-7, 1110. Review.


CTC enumeration and characterization: moving toward personalized medicine.

Toss A, Mu Z, Fernandez S, Cristofanilli M.

Ann Transl Med. 2014 Nov;2(11):108. doi: 10.3978/j.issn.2305-5839.2014.09.06. Review.


CCR5 receptor antagonists block metastasis to bone of v-Src oncogene-transformed metastatic prostate cancer cell lines.

Sicoli D, Jiao X, Ju X, Velasco-Velazquez M, Ertel A, Addya S, Li Z, Andò S, Fatatis A, Paudyal B, Cristofanilli M, Thakur ML, Lisanti MP, Pestell RG.

Cancer Res. 2014 Dec 1;74(23):7103-14. doi: 10.1158/0008-5472.CAN-14-0612.


Circulating tumour cells are linked to plasma D-dimer levels in patients with metastatic breast cancer.

Mego M, Zuo Z, Gao H, Cohen EN, Giordano A, Tin S, Anfossi S, Jackson S, Woodward W, Ueno NT, Valero V, Alvarez RH, Hortobagyi GN, Khoury JD, Cristofanilli M, Reuben JM.

Thromb Haemost. 2015 Mar;113(3):593-8. doi: 10.1160/TH14-07-0597. Epub 2014 Nov 6.


PARP inhibitors for chemoprevention--letter.

Chand SN, Blanco FF, Jimbo M, Tsangaris TN, Cristofanilli M, Yeo CJ, Winter JM, Pishvaian MJ, Brody JR.

Cancer Prev Res (Phila). 2014 Nov;7(11):1170-1. doi: 10.1158/1940-6207.CAPR-14-0220. No abstract available.


Racial disparity in breast cancer survival: the impact of pre-treatment hematologic variables.

Wang C, Civan J, Lai Y, Cristofanilli M, Hyslop T, Palazzo JP, Myers RE, Li B, Ye Z, Zhang K, Xing J, Yang H.

Cancer Causes Control. 2015 Jan;26(1):45-56. doi: 10.1007/s10552-014-0481-4. Epub 2014 Oct 31.


TP53 mutations detected in circulating tumor cells present in the blood of metastatic triple negative breast cancer patients.

Fernandez SV, Bingham C, Fittipaldi P, Austin L, Palazzo J, Palmer G, Alpaugh K, Cristofanilli M.

Breast Cancer Res. 2014 Oct 9;16(5):445. doi: 10.1186/s13058-014-0445-3.


Erythropoiesis stimulating agents and clinical outcomes of invasive breast cancer patients receiving cytotoxic chemotherapy.

Lai Y, Palazzo JP, Cristofanilli M, Hyslop T, Civan J, Avery T, Myers RE, Li B, Ye Z, Xing J, Yang H.

Breast Cancer Res Treat. 2014 Nov;148(1):175-85. doi: 10.1007/s10549-014-3152-y. Epub 2014 Sep 27.


Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination.

Giuliano M, Giordano A, Jackson S, De Giorgi U, Mego M, Cohen EN, Gao H, Anfossi S, Handy BC, Ueno NT, Alvarez RH, De Placido S, Valero V, Hortobagyi GN, Reuben JM, Cristofanilli M.

Breast Cancer Res. 2014 Sep 16;16(5):440. doi: 10.1186/s13058-014-0440-8.


Progressive multiple sclerosis cerebrospinal fluid induces inflammatory demyelination, axonal loss, and astrogliosis in mice.

Cristofanilli M, Rosenthal H, Cymring B, Gratch D, Pagano B, Xie B, Sadiq SA.

Exp Neurol. 2014 Nov;261:620-32. doi: 10.1016/j.expneurol.2014.07.020. Epub 2014 Aug 8.


Inflammatory breast cancer management in the national comprehensive cancer network: the disease, recurrence pattern, and outcome.

Matro JM, Li T, Cristofanilli M, Hughes ME, Ottesen RA, Weeks JC, Wong YN.

Clin Breast Cancer. 2015 Feb;15(1):1-7. doi: 10.1016/j.clbc.2014.05.005. Epub 2014 Jun 23.


AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models.

Mu Z, Klinowska T, Dong X, Foster E, Womack C, Fernandez SV, Cristofanilli M.

J Exp Clin Cancer Res. 2014 May 30;33:47. doi: 10.1186/1756-9966-33-47.


Aldehyde dehydrogenase1 immunohistochemical staining in primary breast cancer cells independently predicted overall survival but did not correlate with the presence of circulating or disseminated tumors cells.

Woodward WA, Krishnamurthy S, Lodhi A, Xiao L, Gong Y, Cristofanilli M, Buchholz TA, Lucci A.

J Cancer. 2014 Apr 7;5(5):360-7. doi: 10.7150/jca.7885. eCollection 2014.


Survival of women with inflammatory breast cancer: a large population-based study.

Dawood S, Lei X, Dent R, Gupta S, Sirohi B, Cortes J, Cristofanilli M, Buchholz T, Gonzalez-Angulo AM.

Ann Oncol. 2014 Jun;25(6):1143-51. doi: 10.1093/annonc/mdu121. Epub 2014 Mar 24.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk